Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01679990 | Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC) | PHASE2 | COMPLETED | 180 | — | — | Nov 5, 2012 | Feb 9, 2019 | Feb 12, 2019 | 34 | United States, Germany +2 |
| Arm | Type | Description |
|---|---|---|
| PLX-PAD Low dose | EXPERIMENTAL | PLX-PAD double low doses |
| PLX-PAD high doses | ACTIVE_COMPARATOR | PLX-PAD double high dose |
| Placebo | PLACEBO_COMPARATOR | Double Placebo doses |
| PLX-PAD high dose +Placebo | EXPERIMENTAL | High dose+Placebo |
| Name | Type | Description |
|---|---|---|
| PLX-PAD Low dose | BIOLOGICAL | - |
| PLX-PAD high doses | BIOLOGICAL | - |
| Double Placebo | BIOLOGICAL | - |
| high dose +Placebo | BIOLOGICAL | - |
Inclusion Criteria: * Adult male or female subjects between 45 to 85 years of age (inclusive) at the time of screening visit. * Subjects with a diagnosis of peripheral artery disease, secondary to atherosclerosis, confirmed by one of the following criteria assessed at the screening visit: * Rest...